The utility of immunohistochemical expression of glypican-3 (GPC3) and enhancer of zeste homologue-2 (EZH2) protein in the diagnosis of liver nodules
Conclusion: GPC3 can be used as a first-line marker for differential diagnoses of HCCs from nonmalignant nodules, CCs, and metastases (accuracy rate: 90.38, 83.67, and 88.89%, respectively). In HCC, overexpression of GPC3 is associated with poor prognostic factors such as large tumor size and high tumor grade. EZH2 is a reliable marker for HCCs compared with nonmalignant nodules (accuracy rate: 92.31%). However, EZH2 is not specific for HCC as all other examined hepatic malignancies were positive as well.
Source: Egyptian Journal of Pathology - Category: Pathology Tags: Original Articles Source Type: research
More News: Bile Duct Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Cirrhosis | Hepatocellular Carcinoma | Liver | Liver Cancer | Pathology | Statistics | Study | Urology & Nephrology